Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma - Wikidata - awgldk - TriplyDB

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

http://www.wikidata.org/entity/Q35525522

about

Management of mantle cell lymphoma in the elderly patient Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Databa Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data Racial differences in mantle cell lymphoma in the United States.Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.Rituximab: current status as therapy for malignant and benign hematologic disorders.Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.Current regimens and novel agents for mantle cell lymphoma.Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.Racial disparities in treatment use for multiple myeloma.How to manage mantle cell lymphoma.Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.Synergistic inhibitory effects of an engineered antibody-like molecule ATF-Fc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.Top ten errors of statistical analysis in observational studies for cancer research.Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.Mantle cell lymphoma epidemiology: a population-based study in France.Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective

P2860

Q26999395-6CD58C64-C7C4-41FE-9E18-11CE3587517D Q30649483-6343C23F-D5D4-44BF-85E9-1DD199C4D165 Q31036587-EDC884E8-DBD5-4FB1-ABF7-599F95BCE8B1 Q34410264-23EAA432-10EB-4E77-AAB8-292444D73F65 Q35637806-9E5DD571-38CE-4986-9A9D-7DBF7FF420E2 Q36210598-F122420B-C8FD-4678-95C4-848CC9DF54A9 Q36278006-18F25BF5-6FE4-4D45-A420-CEFC60BCB5A7 Q36280941-63D787EF-952F-486D-A4A7-A627147AA791 Q36628297-DA05FE79-9E1A-4B2E-87FE-8A389E7AD924 Q36777008-16D2558E-CC0B-42EF-934A-093B2E81A29D Q37718466-00E2ECA8-57D2-43C2-9C41-B93A26957414 Q37738158-6331E64E-1C2E-49E4-8FFE-333A39E857F2 Q37984551-0E829BD7-F125-4B58-BD1B-E316DBB3A61D Q38056669-79E5B27B-0B07-4261-8693-AFC3C0D77D3E Q38224186-B910E632-E1B9-4DDA-AB60-881B77CBC499 Q38673151-7774AACF-1A10-4513-9A33-64B959D49446 Q39022279-F650F6B7-9230-4908-BAA6-BCF568CCC0A8 Q39187610-8956B2BD-C2EE-4296-BBD2-C9C43F01C7D9 Q41674989-6A41ECD3-CD15-433B-A28B-B6A623EC756E Q45174932-60852880-F876-4684-A9C8-CB24A9F9E7FA Q45399228-C26AF208-2378-4AB6-B69D-645D11462421 Q45766463-B7A8448C-F127-42C3-AB83-0F15810B6901 Q46675870-6D01D02C-C493-4439-BFA5-8D109F6AECCB Q46922494-2A7FEA8E-E6E6-4F0C-BB02-85EE66D16027 Q47346382-76B254C2-C8C6-4BCB-A9A2-C4265F74AA55 Q50075321-5292F3F0-2451-48DC-A91E-55650A8570D9 Q52840250-B44A918D-6FA1-45B7-BA00-CEA56A1AF9E5 Q53039853-212DCB59-2633-4E50-A796-92515E14A0FA Q53090896-AAA36845-BFCE-4430-9524-A2A0D8B41533 Q53129637-5979A669-6AB7-4E62-98B9-F3F5561B03DA Q53134173-84EB51B8-5CCF-41D2-A4FF-7EF73EA4B1DD

P2860

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

http://www.wikidata.org/entity/Q35525522

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Addition of rituximab to chemo ...... ents with mantle cell lymphoma

@ast

Addition of rituximab to chemo ...... ents with mantle cell lymphoma

@en

type

label

Addition of rituximab to chemo ...... ents with mantle cell lymphoma

@ast

Addition of rituximab to chemo ...... ents with mantle cell lymphoma

@en

prefLabel

Addition of rituximab to chemo ...... ents with mantle cell lymphoma

@ast

Addition of rituximab to chemo ...... ents with mantle cell lymphoma

@en

P1433

Q35525522-3381E79C-0773-47DA-B0F5-D2B768291949

P1476

Q35525522-BB48D08F-29FD-48A0-97BA-F956EC057D70

P2093

Q35525522-260CD8F5-6499-4F2A-9BF3-7CC497302DF7

Q35525522-7798E56B-88B0-4B72-A0DE-149A3CA4ECBC

Q35525522-A7D57FE8-3CD9-4038-B746-E301ACA77806

Q35525522-B62B6655-3B00-4E8D-9C61-63999D8A24E0

Q35525522-D6B32E42-502D-46C2-AA61-D52802DB997A

P2860

Q35525522-0E501B58-F049-4342-A5A0-91889DE5CB20

Q35525522-10C5126D-5688-482A-B0A8-B1BBDAB8C10A

Q35525522-11829884-AE9F-4A05-BCEB-E74C735F34AA

Q35525522-168A909E-09B3-4FB2-BD3C-5E70CAAD8C4F

Q35525522-29EC361C-9225-49C2-9AF9-9ED4029F4614

Q35525522-29FF4AC0-F769-46A3-A57C-70B98CD05677

Q35525522-2DF09536-A9DE-4580-B543-C7035CA54D91

Q35525522-43844C8D-292D-46B3-BD89-D942D7C36771

Q35525522-57A01FBC-58F5-4174-A9BD-F813EFE74C54

Q35525522-59DBF259-2276-402B-8477-7FCC9C6D3E45

P304

Q35525522-A4153E85-891F-49C5-8B71-852581C8AA1A

P31

Q35525522-A4078FA8-EFF0-47E3-9D30-1FBB8AEAEFE0

P356

Q35525522-BE2E847E-03C6-442D-9F69-492408610D99

P407

Q35525522-B653DA6F-D277-477F-9C37-E4C335B3EEA6

P433

Q35525522-15EAAE65-B9EB-486E-B204-1701BE2ACF4E

P478

Q35525522-8AB2B3F0-8929-4A28-93D2-5B6664CBC4E2

P577

Q35525522-F57724FE-208A-4F78-8A23-6A965578AFE6

P5875

Q35525522-13C8A1DD-90B0-4A2A-A049-99C421C64914

P698

Q35525522-DDBB3E26-596E-4EA6-AEA9-2F7F84B53FCC

P921

Q35525522-DA89FB73-36DE-4B43-850C-04EBCBF4C3E3

P932

Q35525522-F51ADAA0-26BB-41E7-B359-46C574AA97C9

P356

BLOOD-2011-04-348367

P1433

P1476

Addition of rituximab to chemo ...... ents with mantle cell lymphoma

@en

P2093

Joseph Mikhael

http://www.w3.org/2001/XMLSchema#string

Mark Danese

http://www.w3.org/2001/XMLSchema#string

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

Michelle Gleeson

http://www.w3.org/2001/XMLSchema#string

Robert Griffiths

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Development of a comorbidity index using physician claims data.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Utility of the SEER-Medicare data to identify chemotherapy use.

Identifying cancer relapse using SEER-Medicare data.

Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.

P304

4808-4816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-04-348367

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51601570

http://www.w3.org/2001/XMLSchema#string

P698

21873544

http://www.w3.org/2001/XMLSchema#string

P921

P932

3208292

http://www.w3.org/2001/XMLSchema#string